Completed PHASE1 INTERVENTIONAL 6-arm NCT00941018

Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers

A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers

Sponsor: Resolvyx Pharmaceuticals, Inc

Conditions Healthy

Interventions RX-10001

Updated 6 times since 2017 Last updated: Dec 1, 2009 Started: Jun 30, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00941018, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Resolvyx Pharmaceuticals, Inc, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Resolvyx Pharmaceuticals, Inc

Data source: Resolvyx Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zuidlaren, Netherlands